Marco Gerlinger

15.1k citations

62 papers · 2.4k indexed · h-index 22

Impact in

Cancer Research top 1%
- Cancer Genomics and Diagnostics
Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Colorectal Cancer Treatments and Studies

Papers in ⓘ

Cancer Research 30
- Cancer Genomics and Diagnostics 29
Modeling and Simulation 5

Co-authors: Charles Swanton (13 shared papers)Lajos Pusztai (2 shared papers)Timothy A. Yap (1 shared paper)P. Andrew Futreal (2 shared papers)Louise J. Barber (10 shared papers)Matthew N. Davies (2 shared papers)Rebecca A. Burrell (4 shared papers)Nicholas McGranahan (4 shared papers)
Journals: Journal of Clinical Oncology (10 papers)Annals of Oncology (4 papers)Cancer Research (4 papers)European Journal of Cancer (3 papers)The Journal of Pathology (3 papers)
Partner nations: United Kingdom United States Denmark

In The Last Decade

Marco Gerlinger

58 papers receiving 2.3k citations

Peers

Countries citing papers authored by Marco Gerlinger

Since Specialization

Citations

This map shows the geographic impact of Marco Gerlinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Gerlinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Gerlinger more than expected).

Fields of papers citing papers by Marco Gerlinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Gerlinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Gerlinger. The network helps show where Marco Gerlinger may publish in the future.

Co-authors

The 25 scholars most cited alongside Marco Gerlinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Marco Gerlinger Line = papers co-authored together Marco Gerlinger links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 62 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Intratumor Heterogeneity: Seeing the Wood for the Trees Science Translational Medicine ·Timothy A. Yap, Marco Gerlinger, P. Andrew Futreal, Lajos Pusztai, Charles Swanton	2012	381
2	How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine British Journal of Cancer ·Marco Gerlinger, Charles Swanton	2010	325
3	Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine Trends in cancer ·Kamil Lipiński, Louise J. Barber, Matthew N. Davies, Matthew Ashenden, Andrea Sottoriva, Marco Gerlinger	2016	172
4	Cancer: Evolution Within a Lifetime Annual Review of Genetics ·Marco Gerlinger, Nicholas McGranahan, Sally M. Dewhurst, Rebecca A. Burrell, Ian Tomlinson, Charles Swanton	2014	130
5	Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers European Urology ·Sakshi Gulati, Pierre Martinez, Tejal Joshi, Nicolai J. Birkbak, Cláudio R. Santos, Andrew J. Rowan, Lisa Pickering, Martin Gore, James Larkin, Zoltán Szállási, Paul A. Bates, Charles Swanton, Marco Gerlinger	2014	126
6	Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials The Lancet Oncology ·N. Juul, Zoltán Szállási, Aron C. Eklund, Qiyuan Li, Rebecca A. Burrell, Marco Gerlinger, Vicente Valero, Eleni Andreopoulou, Francisco J. Esteva, W. Fraser Symmans, Christine Desmedt, Benjamin Haibe‐Kains, Christos Sotiriou, Lajos Pusztai, Charles Swanton	2010	99
7	Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment Journal for ImmunoTherapy of Cancer ·Alice Newey, B Griffiths, Justine Michaux, Hui Song Pak, Brian J. Stevenson, Andrew Woolston, Maria Semiannikova, Georgia Spain, Louise J. Barber, Nik Matthews, Sheela Rao, David Watkins, Ian Chau, George Coukos, Julien Racle, David Gfeller, Naureen Starling, David Cunningham, Michal Bassani‐Sternberg, Marco Gerlinger	2019	91
8	Genome‐wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target The Journal of Pathology ·Marco Gerlinger, Cláudio R. Santos, Bradley Spencer‐Dene, Pierre Martinez, David Endesfelder, Rebecca A. Burrell, Marcus Vetter, Ming Jiang, Rebecca E. Saunders, Gavin Kelly, Karl Dykema, Nathalie Rioux‐Leclercq, Gordon Stamp, Jean Jacques Patard, James Larkin, Michael Howell, Charles Swanton	2012	89
9	Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications European Urology ·Marco Gerlinger, James W.F. Catto, Torben F. Ørntoft, Francisco X. Real, Ellen C. Zwarthoff, Charles Swanton	2014	87
10	Egr-1 Induces the Expression of Its Corepressor Nab2 by Activation of the Nab2 Promoter Thereby Establishing a Negative Feedback Loop Journal of Biological Chemistry ·Joerg Kumbrink, Marco Gerlinger, Judith P. Johnson	2005	80
11	Ultra‐deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas The Journal of Pathology ·Marco Gerlinger, Sergio A. Quezada, Karl S. Peggs, Andrew JS Furness, Rosalie Fisher, Teresa Marafioti, Vishvesh Shende, Nicholas McGranahan, Andrew J. Rowan, Steven Hazell, David Hamm, Harlan Robins, Lisa Pickering, Martin Gore, David Nicol, James Larkin, Charles Swanton	2013	74
12	Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference European Journal of Cancer ·Daniel S.W. Tan, Marco Gerlinger, Bin Tean Teh, Charles Swanton	2010	66
13	Parallel evolution of tumour subclones mimics diversity between tumours The Journal of Pathology ·Pierre Martinez, Nicolai J. Birkbak, Marco Gerlinger, Nicholas McGranahan, Rebecca A. Burrell, Andrew J. Rowan, Tejal Joshi, Rosalie Fisher, James Larkin, Zoltán Szállási, Charles Swanton	2013	63
14	The promise of circulating tumor cell analysis in cancer management Genome biology ·Joaquı́n Mateo, Marco Gerlinger, Daniel Nava Rodrigues, Johann S. de Bono	2014	51
15	Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale Current Opinion in Genetics & Development ·Louise J. Barber, Matthew N. Davies, Marco Gerlinger	2014	48
16	Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study Clinical Colorectal Cancer ·Hamzeh Kayhanian, E. Goode, Francesco Sclafani, Joo Ern Ang, Marco Gerlinger, David González de Castro, Scott T.C. Shepherd, Clare Peckitt, Sheela Rao, David Watkins, Ian Chau, David Cunningham, Naureen Starling	2017	46
17	Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study ESMO Open ·David K. Lau, Eleftheria Kalaitzaki, David N. Church, Hardev Pandha, Ian Tomlinson, Nicola Annels, Marco Gerlinger, Francesco Sclafani, Gillian Smith, Ruwaida Begum, Richard Crux, Angela Gillbanks, Sarah Wordsworth, Ian Chau, Naureen Starling, David Cunningham, Tony Dhillon	2020	44
18	Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer Nature Communications ·Katharina von Loga, Andrew Woolston, Marco Punta, Louise J. Barber, B Griffiths, Maria Semiannikova, Georgia Spain, Benjamin Challoner, Kerry Fenwick, Ronald Simon, Andreas H. Marx, Guido Sauter, Stefano Lise, Nik Matthews, Marco Gerlinger	2020	43
19	Circulating tumour DNA, a promising biomarker for the management of colorectal cancer Critical Reviews in Oncology/Hematology ·Shelize Khakoo, Alexandros Georgiou, Marco Gerlinger, David Cunningham, Naureen Starling	2017	34
20	Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma BMC Medicine ·Shanthini Mary Crusz, Yen Zhi Tang, Shah‐Jalal Sarker, Warner Prevoo, Irfan Kiyani, Luis Beltrán, John Peters, Anju Sahdev, Axel Bex, Thomas Powles, Marco Gerlinger	2016	28

About Marco Gerlinger

Marco Gerlinger is a scholar working on Cancer Research, Modeling and Simulation, Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 62 papers that have together received 2.4k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (29 papers), Genetic factors in colorectal cancer (14 papers), Colorectal Cancer Treatments and Studies (13 papers), Gastric Cancer Management and Outcomes (12 papers), Renal cell carcinoma treatment (6 papers), Cancer Immunotherapy and Biomarkers (6 papers), Esophageal Cancer Research and Treatment (6 papers) and Lung Cancer Treatments and Mutations (5 papers). The work is most often cited by research in Cancer Research (1.2k citations), Oncology (955 citations), Modeling and Simulation (123 citations), Pulmonary and Respiratory Medicine (647 citations) and Pathology and Forensic Medicine (290 citations). Marco Gerlinger has collaborated with scholars based in United Kingdom, United States and Denmark. Frequent co-authors include Charles Swanton, Lajos Pusztai, Timothy A. Yap, P. Andrew Futreal, Louise J. Barber, Matthew N. Davies, Rebecca A. Burrell, Nicholas McGranahan, Naureen Starling and Andrea Sottoriva. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, European Journal of Cancer and The Journal of Pathology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact